Lydia Pui Yee Loke (Lydia Loke)

Publication Activity (10 Years)

Years Active: 2020-2021
Publications (10 Years): 3

Top Topics

Metastatic Breast Cancer

Epidermal Growth Factor Receptor

Randomized Controlled Trial

Combination Therapy

Top Venues

Cancer reports (Hoboken, N.J.)

Journal of medical economics

Expert review of pharmacoeconomics & outcomes research

This page only lists publications with an associated author ORCID identifier.

Publications

Li-Jen Cheng, Lydia Pui Yee Loke, Elaine Hsuen Lim, Fiona Pearce, Mohamed Ismail Abdul Aziz, Kwong Ng
Cost-effectiveness of pertuzumab and trastuzumab biosimilar combination therapy as initial treatment for HER2-positive metastatic breast cancer in Singapore. Expert review of pharmacoeconomics & outcomes research 21 (3) (2021)
Lydia Pui Yee Loke, Soo-Chin Lee, Fiona Pearce, Mohamed Ismail Abdul Aziz, Mohamed Ismail Abdul Aziz
Cost-effectiveness of ribociclib as initial treatment for premenopausal women with advanced breast cancer in Singapore. Cancer reports (Hoboken, N.J.) 4 (1) (2020)
Mohamed Ismail Abdul Aziz, Ling Eng Tan, Wan Hui Gloria Tan, Chee Keong Toh, Lydia Pui Yee Loke, Fiona Pearce, Kwong Ng
Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer. Journal of medical economics 23 (9) (2020)